Company profile for Adlai Nortye

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Adlai Nortye is a science-led biopharmaceutical company dedicated to discovering, developing and commercializing new drugs in the field of oncology/immuno-oncology. Our mission is to improve patient lives by developing differentiated, innovative medicines that help people live better and longer. We have 23 patents granted and 7 PCT published. With extensive experience in peptide and protein drugs, we have expanded our expertis...
Adlai Nortye is a science-led biopharmaceutical company dedicated to discovering, developing and commercializing new drugs in the field of oncology/immuno-oncology. Our mission is to improve patient lives by developing differentiated, innovative medicines that help people live better and longer. We have 23 patents granted and 7 PCT published. With extensive experience in peptide and protein drugs, we have expanded our expertise into small molecules and therapeutic antibodies. Through close collaboration with global partners, we have successfully positioned ourselves in the fields of immuno-oncology/oncology.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
China
Address
Address
21 Floor, Building No.2, No.452, 6th street, Hangzhou Economic & Technological...
Telephone
Telephone
0571-28918366
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/21/3192755/0/en/Adlai-Nortye-to-Participate-in-Upcoming-Investor-Conferences.html

GLOBENEWSWIRE
21 Nov 2025

https://www.globenewswire.com/news-release/2025/10/22/3170782/0/en/Adlai-Nortye-to-Present-Short-Talk-on-AN4035-Preclinical-Results-at-AACR-NCI-EORTC-International-Conference-on-Molecular-Targets-and-Cancer-Therapeutics.html

GLOBENEWSWIRE
22 Oct 2025

https://www.globenewswire.com/news-release/2025/04/10/3059197/0/en/Adlai-Nortye-to-Present-Research-Findings-at-AACR-Annual-Meeting-2025.html

GLOBENEWSWIRE
10 Apr 2025

https://www.globenewswire.com/news-release/2024/08/08/2926900/0/en/Adlai-Nortye-Appoints-Roger-Sawhney-M-D-to-Its-Board-of-Directors.html

GLOBENEWSWIRE
08 Aug 2024

https://www.globenewswire.com/news-release/2024/05/24/2887749/0/en/Adlai-Nortye-Ltd-to-Present-Encouraging-Data-of-the-Combination-of-AN0025-and-Definitive-Chemoradiotherapy-dCRT-at-ASCO-2024.html

GLOBENEWSWIRE
23 May 2024

https://www.globenewswire.com/news-release/2024/05/22/2886439/0/en/Adlai-Nortye-Announces-First-Patient-Dosed-in-Randomized-Phase-II-Clinical-Trial-of-Palupiprant-AN0025-for-the-Treatment-of-Locally-Advanced-Rectal-Cancer-with-Radiation-Therapy.html

GLOBENEWSWIRE
22 May 2024

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty